Rheum Roundup: Platelet-rich Plasma Benefits, Low Tourniquet Pressure TKA, and More

Recent research has focused on platelet-rich plasma (PRP) and its benefits in orthopedic surgery and rheumatic conditions such as osteoarthritis (OA). Here, we’ve reviewed some of the latest PRP studies.

Strong electroacupuncture may help treat chronic pain in knee OA patients.

Total knee arthroplasty patients may have similar bleeding outcomes whether they receive lower tourniquet pressure (systolic blood pressure [SBP] 120 mmHg) or conventional tourniquet pressure (SBP 150 mmHg).

The mortality rate associated with falls in older adults is climbing. A new study found that an in-home exercise program may help reduce the risk in patients with a history of falls.

Although rheumatoid arthritis (RA) is more common in women than men, men with RA have a greater risk of cardiovascular events than women with the disease.

A recent review concluded that more research is needed on tapering biologic therapy in RA patients, and future studies should focus on patient perspectives.

Patients with severe diabetes have a higher risk for 90-day readmission after shoulder arthroplasty.

Researchers recently analyzed the migration patterns of total joint arthroplasty patients.

Patients with Parkinson’s disease (PD) who undergo total hip replacement have a greater risk for revision but not short-term mortality compared to non-PD patients.

Systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome patients taking antithrombotics may be able to safely undergo transjugular renal biopsy without increasing their risk of bleeding.

Switching from methotrexate monotherapy to combination with an originator or biosimilar tumor necrosis factor inhibitor may be a cost-effective option for RA patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

Tocilizumab monotherapy may be more effective in repairing existing bone erosions in early-stage RA patients than combination methotrexate with adalimumab.

A recent study identified predictors of low disease activity and clinical remission in SLE patients treated with belimumab.

Remission for RA patients receiving anti-tumor necrosis factor therapy is not common, according to new research.